Semmelweis University and MSD Pharma Hungary have officially renewed and expanded their long-standing collaboration with a strategic agreement signed on May 22, 2025. Building on over two decades of partnership, the agreement sets a new course for joint initiatives in clinical research, diagnostics, artificial intelligence, and health education. The collaboration aims to explore cutting-edge areas such as liquid biopsy development, cancer diagnostics, AI-based patient pathway optimization, and data-driven healthcare models.
Through this strategic alliance, the two institutions plan to co-develop innovative medical technologies and expand the scope of clinical trials — currently spanning oncology, cardiovascular diseases, pulmonology, and infectious diseases. The partnership also places strong emphasis on supporting young researchers and medical students by providing access to advanced research programs, digital health tools, and global pharmaceutical expertise.
With over 50 joint clinical research projects completed over the past decade, the partnership is positioned to significantly contribute to both national and international healthcare challenges. It also supports Semmelweis University’s broader mission of becoming a leading center for medical innovation in Central and Eastern Europe. The new agreement further reinforces the university’s Science Park initiative and strengthens Hungary’s role in shaping the future of patient-centered, technology-driven healthcare.
Source: Semmelweis University
About the Author
